Biography
Dr. Parikh is a clinician scientist who cares for patients with and studies inherited (genetic) cardiovascular disease. She is the director of the Stanford Center for Inherited Cardiovascular Disease (SCICD) which is one of the largest of its kind in the country. SCICD integrates clinical and basic science with the expert care of patients with genetic cardiovascular conditions (e.g., cardiomyopathies, arrhythmias and vascular diseases). It provides cutting edge care for thousands of patients and families across the lifespan and integrates medical, surgical and genetics care. Our team includes physicians, nurses, advanced practice providers, genetic counselors, exercise physiologists and scientists.
Dr. Parikh's own clinical practice and laboratory are focused on the genetics of cardiomyopathies and their associated arrhythmogenic substrates. She completed clinical cardiology fellowship at Stanford School of Medicine and her medical residency at the University of California, San Francisco. Funded by multiple ÌÇÐÄ´«Ã½ grants from the NIH, her lab seeks to identify novel mechanisms and therapeutic technologies for genetic cardiomyopathy as well as better understand the natural histories of patients affected by these diseases.
Dr. Parikh's own clinical practice and laboratory are focused on the genetics of cardiomyopathies and their associated arrhythmogenic substrates. She completed clinical cardiology fellowship at Stanford School of Medicine and her medical residency at the University of California, San Francisco. Funded by multiple ÌÇÐÄ´«Ã½ grants from the NIH, her lab seeks to identify novel mechanisms and therapeutic technologies for genetic cardiomyopathy as well as better understand the natural histories of patients affected by these diseases.
View Full Biography
Professional Summary
Education & Certifications
- Medical Education: Stanford University School of Medicine (2011) CA
- Fellowship: Stanford University Cardiovascular Medicine Fellowship (2017) CA
- Board Certification: American Board of Internal Medicine, Internal Medicine (2014)
-
- Residency: University of California San Francisco (2014) CA
Honors & Awards
- Excellence in Cardiology Fellowship Award, American College of Cardiology (05/2016)
- Mentored Clinical Scientist Career Development Award (K08), National Institutes of Health (2019-2024)
- Ruth L. Kirschtein NRSA NIH Postdoctoral Fellowship Grant, National Institutes of Health (2/2016-9/2018)
-
- Sarnoff Cardiovascular Research Foundation Fellowship, Sarnoff Cardiovascular Foundation (2009-2010)
- Sarnoff Scholar Award, Sarnoff Cardiovascular Research Foundation (10/2018-10/2019)
- Women in Cardiology Award for Trainee Excellence, American Heart Association (11/2016)
Publications
-
Behavioral coping strategies in a cichlid fish: the role of social status and acute stress response in direct and displaced aggression
Clement, T. S., Parikh, V., Schrumpf, M., & Fernald, R. D. (2005). Behavioral coping strategies in a cichlid fish: the role of social status and acute stress response in direct and displaced aggression. HORMONES AND BEHAVIOR, 47(3), 336–42. -
Androgen level and male social status in the African cichlid, Astatotilapia burtoni
Parikh, V. N., Clement, T. S., & Fernald, R. D. (2006). Androgen level and male social status in the African cichlid, Astatotilapia burtoni. BEHAVIOURAL BRAIN RESEARCH, 166(2), 291–95. -
Physiological consequences of social descent: studies in Astatotilapia burtoni
Parikh, V. N., Clement, T., & Fernald, R. D. (2006). Physiological consequences of social descent: studies in Astatotilapia burtoni. JOURNAL OF ENDOCRINOLOGY, 190(1), 183–90. -
-
Early Outcomes After Extracardiac Conduit Fontan Operation Without Cardiopulmonary Bypass
McCammond, A. N., Kuo, K., Parikh, V. N., Abdullah, K., Balise, R., Hanley, F. L., & Roth, S. J. (2012). Early Outcomes After Extracardiac Conduit Fontan Operation Without Cardiopulmonary Bypass. PEDIATRIC CARDIOLOGY, 33(7), 1078–85. -
Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension
Bertero, T., Oldham, W. M., Cottrill, K. A., Pisano, S., Vanderpool, R. R., Yu, Q., … Chan, S. Y. (2016). Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. JOURNAL OF CLINICAL INVESTIGATION, 126(9), 3313–35. -
Delivering Clinical Grade Sequencing and Genetic Test Interpretation for Cardiovascular Medicine.
Harper, A. R., Parikh, V. N., Goldfeder, R. L., Caleshu, C., & Ashley, E. A. (2017). Delivering Clinical Grade Sequencing and Genetic Test Interpretation for Cardiovascular Medicine. Circulation. Cardiovascular Genetics, 10(2). -
Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition.
Parikh, V. N., Liu, J., Shang, C., Woods, C., Chang, A. C., Zhao, M., … Ashley, E. A. (2018). Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition. American Journal of Physiology. Heart and Circulatory Physiology. -
Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy.
Parikh, V. N., Caleshu, C., Reuter, C., Lazzeroni, L. C., Ingles, J., Garcia, J., … Ashley, E. (2019). Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circulation. Heart Failure, 12(3), e005371. -
Mind the Gap: Current Challenges and Future State of Heart Failure Care
McDonald, M. A., Ashley, E. A., Fedak, P. W. M., Hawkins, N., Januzzi, J. L., McMurray, J. J. V., … Virani, S. (2017). Mind the Gap: Current Challenges and Future State of Heart Failure Care. CANADIAN JOURNAL OF CARDIOLOGY, 33(11), 1434–49. -
Next-Generation Sequencing in Cardiovascular Disease Present Clinical Applications and the Horizon of Precision Medicine
Parikh, V. N., & Ashley, E. A. (2017). Next-Generation Sequencing in Cardiovascular Disease Present Clinical Applications and the Horizon of Precision Medicine. CIRCULATION, 135(5), 406–9. -
Wrestling the Giant: New Approaches for Assessing Titin Variant Pathogenicity.
Helle, E., & Parikh, V. N. (2016). Wrestling the Giant: New Approaches for Assessing Titin Variant Pathogenicity. Circulation. Cardiovascular Genetics, 9(5), 392–394. -
Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure.
Cordero, P., Parikh, V. N., Chin, E. T., Erbilgin, A., Gloudemans, M. J., Shang, C., … Ashley, E. A. (2019). Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure. Nature Communications, 10(1), 2760. -
Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Due to a Human Myosin Regulatory Light Chain Mutation.
Zaleta-Rivera, K., Dainis, A., Ribeiro, A. J., Sanchez Cordero, P., Rubio, G., Shang, C., … Ashley, E. A. (2019). Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Due to a Human Myosin Regulatory Light Chain Mutation. Circulation. -
Pathological overlap of Arrhythmogenic Right Ventricular Cardiomyopathy and Cardiac Sarcoidosis.
Kerkar, A., Hazard, F., Caleshu, C. A., Shah, R. L., Reuter, C., Ashley, E. A., & Parikh, V. N. (2019). Pathological overlap of Arrhythmogenic Right Ventricular Cardiomyopathy and Cardiac Sarcoidosis. Circulation. Genomic and Precision Medicine. -
Circulating microRNAs as Biomarkers for Sudden Cardiac Death: Truth in the Serum?
Parikh, V. N. (2020). Circulating microRNAs as Biomarkers for Sudden Cardiac Death: Truth in the Serum? JACC. Clinical Electrophysiology, 6(1), 80–82. -
Stretch-Induced Biased Signaling in Angiotensin II Type 1 and Apelin Receptors for the Mediation of Cardiac Contractility and Hypertrophy.
Seo, K., Parikh, V. N., & Ashley, E. A. (2020). Stretch-Induced Biased Signaling in Angiotensin II Type 1 and Apelin Receptors for the Mediation of Cardiac Contractility and Hypertrophy. Frontiers in Physiology, 11, 181. -
Patient-Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left Heart Syndrome.
Paige, S. L., Galdos, F. X., Lee, S., Chin, E. T., Ranjbarvaziri, S., Feyen, D. A., … Wu, S. M. (2020). Patient-Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left Heart Syndrome. Circulation, 142(16), 1605–8. -
Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association
Musunuru, K., Hershberger, R. E., Day, S. M., Klinedinst, N. J., Landstrom, A. P., Parikh, V. N., … Sturm, A. C. (2020). Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. CIRCULATION-GENOMIC AND PRECISION MEDICINE, 13(4), e000067. -
Promise and Peril of Population Genomics for the Development of Genome-First Approaches in Mendelian Cardiovascular Disease.
Parikh, V. N. (2021). Promise and Peril of Population Genomics for the Development of Genome-First Approaches in Mendelian Cardiovascular Disease. Circulation. Genomic and Precision Medicine, CIRCGEN120002964. -
Arrhythmogenic Cardiomyopathy: Mechanisms, Genetics, and Their Clinical Implications
Reuter, C. M., Dries, A. M., & Parikh, V. N. (2021). Arrhythmogenic Cardiomyopathy: Mechanisms, Genetics, and Their Clinical Implications. CURRENT CARDIOVASCULAR RISK REPORTS, 15(5). -
The genetic architecture of Plakophilin 2 cardiomyopathy.
Dries, A. M., Kirillova, A., Reuter, C. M., Garcia, J., Zouk, H., Hawley, M., … Parikh, V. N. (2021). The genetic architecture of Plakophilin 2 cardiomyopathy. Genetics in Medicine : Official Journal of the American College of Medical Genetics. -
Iron Deficiency as a Potential Modulator of Subclinical Deficiencies in Cardiac Performance and Exercise Capacity.
Elezaby, A., Parikh, V. N., & Nayor, M. (2021). Iron Deficiency as a Potential Modulator of Subclinical Deficiencies in Cardiac Performance and Exercise Capacity. Journal of Cardiac Failure, 27(7), 822–824. -
Mapping the human genetic architecture of COVID-19.
Mapping the human genetic architecture of COVID-19. (2021). Nature. -
Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy.
Nauffal, V., Marstrand, P., Han, L., Parikh, V. N., Helms, A. S., Ingles, J., … Ho, C. Y. (2021). Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal. -
Phenotypic Expression, Natural History and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants.
Gigli, M., Stolfo, D., Graw, S., Merlo, M., Gregorio, C., Chen, S. N., … Mestroni, L. (2021). Phenotypic Expression, Natural History and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation. -
Association of Titin Variations With Late-Onset Dilated Cardiomyopathy.
Cannata, A., Merlo, M., Dal Ferro, M., Barbati, G., Manca, P., Paldino, A., … Sinagra, G. (2022). Association of Titin Variations With Late-Onset Dilated Cardiomyopathy. JAMA Cardiology. -
The Response to Cardiac Resynchronization Therapy in LMNA cardiomyopathy.
Sidhu, K., Castrini, A. I., Parikh, V., Reza, N., Owens, A., Tremblay-Gravel, M., … Lakdawala, N. K. (2022). The Response to Cardiac Resynchronization Therapy in LMNA cardiomyopathy. European Journal of Heart Failure. -
Wnt Signaling Interactor WTIP (Wilms Tumor Interacting Protein) Underlies Novel Mechanism for Cardiac Hypertrophy.
De Jong, H. N., Dewey, F. E., Cordero, P., Victorio, R. A., Kirillova, A., Huang, Y., … Ashley, E. A. (2022). Wnt Signaling Interactor WTIP (Wilms Tumor Interacting Protein) Underlies Novel Mechanism for Cardiac Hypertrophy. Circulation. Genomic and Precision Medicine, 101161CIRCGEN121003563. -
Emerging Genotype-Phenotype Associations in Dilated Cardiomyopathy.
Njoroge, J. N., Mangena, J. C., Aribeana, C., & Parikh, V. N. (2022). Emerging Genotype-Phenotype Associations in Dilated Cardiomyopathy. Current Cardiology Reports. -
Deconvoluting complex correlates of COVID-19 severity with a multi-omic pandemic tracking strategy.
Parikh, V. N., Ioannidis, A. G., Jimenez-Morales, D., Gorzynski, J. E., De Jong, H. N., Liu, X., … Ashley, E. A. (2022). Deconvoluting complex correlates of COVID-19 severity with a multi-omic pandemic tracking strategy. Nature Communications, 13(1), 5107. -
Scalable Functional Assays for the Interpretation of Human Genetic Variation.
Tabet, D., Parikh, V., Mali, P., Roth, F. P., & Claussnitzer, M. (2022). Scalable Functional Assays for the Interpretation of Human Genetic Variation. Annual Review of Genetics. -
Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
Gimeno, J. R., Olivotto, I., RodrÃguez, A. I., Ho, C. Y., Fernández, A., Quiroga, A., … Lakdawala, N. K. (2022). Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure, 9(4), 2189–2198. -
Generation of two induced pluripotent stem cell lines from dilated cardiomyopathy patients carrying TTN mutations.
Zhang, T. T., Zhao, S. R., Alamana, C., Shen, M., Parikh, V., Wheeler, M. T., & Wu, J. C. (2022). Generation of two induced pluripotent stem cell lines from dilated cardiomyopathy patients carrying TTN mutations. Stem Cell Research, 65, 102941. -
Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy.
Nauffal, V., Marstrand, P., Han, L., Parikh, V. N., Helms, A. S., Ingles, J., … Ho, C. Y. (2021). Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 42(38), 3932–3944. -
Intrinsic Atrial Myopathy Precedes Left Ventricular Dysfunction and Predicts Atrial Fibrillation in Lamin A/C Cardiomyopathy.
Tremblay-Gravel, M., Ichimura, K., Picard, K., Kawano, Y., Dries, A. M., Haddad, F., … Parikh, V. N. (2022). Intrinsic Atrial Myopathy Precedes Left Ventricular Dysfunction and Predicts Atrial Fibrillation in Lamin A/C Cardiomyopathy. Circulation. Genomic and Precision Medicine, e003480. -
Variant Location Is a Novel Risk Factor for Individuals With Arrhythmogenic Cardiomyopathy Due to a Desmoplakin (DSP) Truncating Variant.
Hoorntje, E. T., Burns, C., Marsili, L., Corden, B., Parikh, V. N., Te Meerman, G. J., … Ingles, J. (2022). Variant Location Is a Novel Risk Factor for Individuals With Arrhythmogenic Cardiomyopathy Due to a Desmoplakin (DSP) Truncating Variant. Circulation. Genomic and Precision Medicine, e003672. -
Cardiac splicing as a diagnostic and therapeutic target.
Gotthardt, M., Badillo-Lisakowski, V., Parikh, V. N., Ashley, E., Furtado, M., Carmo-Fonseca, M., … Leinwand, L. (2023). Cardiac splicing as a diagnostic and therapeutic target. Nature Reviews. Cardiology. -
Proactive Variant Effect Mapping Aids Diagnosis in Pediatric Cardiac Arrest.
Floyd, B. J., Weile, J., Kannankeril, P. J., Glazer, A. M., Reuter, C. M., MacRae, C. A., … Parikh, V. N. (2023). Proactive Variant Effect Mapping Aids Diagnosis in Pediatric Cardiac Arrest. Circulation. Genomic and Precision Medicine. -
Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry (Sarcomeric Human Cardiomyopathy).
Alaiwi, S. A., Roston, T. M., Marstrand, P., Claggett, B. L., Parikh, V. N., Helms, A. S., … Ho, C. Y. (2023). Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry (Sarcomeric Human Cardiomyopathy). Circulation. -
An Atlas of Variant Effects to understand the genome at nucleotide resolution.
Fowler, D. M., Adams, D. J., Gloyn, A. L., Hahn, W. C., Marks, D. S., Muffley, L. A., … Hurles, M. E. (2023). An Atlas of Variant Effects to understand the genome at nucleotide resolution. Genome Biology, 24(1), 147. -
A Precision Approach to Family Screening in ARVC.
Heidenreich, P. A., Haddad, F., & Parikh, V. N. (2023). A Precision Approach to Family Screening in ARVC. Journal of the American College of Cardiology, 82(3), 226–227. -
Mislocalization of pathogenic RBM20 variants in dilated cardiomyopathy is caused by loss-of-interaction with Transportin-3.
Kornienko, J., RodrÃguez-MartÃnez, M., Fenzl, K., Hinze, F., Schraivogel, D., Grosch, M., … Steinmetz, L. M. (2023). Mislocalization of pathogenic RBM20 variants in dilated cardiomyopathy is caused by loss-of-interaction with Transportin-3. Nature Communications, 14(1), 4312. -
Genetic Risk Stratification in Arrhythmogenic Left Ventricular Cardiomyopathy.
Desai, Y. B., & Parikh, V. N. (2023). Genetic Risk Stratification in Arrhythmogenic Left Ventricular Cardiomyopathy. Cardiac Electrophysiology Clinics, 15(3), 391–399. -
Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure.
Cannie, D. E., Syrris, P., Protonotarios, A., Bakalakos, A., Pruny, J.-F. F., Ditaranto, R., … Elliott, P. M. (2023). Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure. European Heart Journal. -
Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-ß-Blocking R-Enantiomer Carvedilol.
Seo, K., Yamamoto, Y., Kirillova, A., Kawana, M., Yadav, S., Huang, Y., … Ashley, E. A. (2023). Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-ß-Blocking R-Enantiomer Carvedilol. Circulation. -
Epistasis regulates genetic control of cardiac hypertrophy.
Wang, Q., Tang, T. M., Youlton, N., Weldy, C. S., Kenney, A. M., Ronen, O., … Ashley, E. A. (2023). Epistasis regulates genetic control of cardiac hypertrophy. MedRxiv : the Preprint Server for Health Sciences. -
Genetic architecture of cardiac dynamic flow volumes.
Gomes, B., Singh, A., O'Sullivan, J. W., Schnurr, T. M., Goddard, P. C., Loong, S., … Ashley, E. A. (2023). Genetic architecture of cardiac dynamic flow volumes. Nature Genetics. -
Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension.
Tai, Y.-Y. Y., Yu, Q., Tang, Y., Sun, W., Kelly, N. J., Okawa, S., … Chan, S. Y. (2024). Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension. Science Translational Medicine, 16(729), eadd2029. -
Regional Variation in Cardiovascular Genes Enables a Tractable Genome Editing Strategy.
Krysov, V. A., Wilson, R. H., Ten, N. S., Youlton, N., De Jong, H. N., Sutton, S., … Parikh, V. N. (2024). Regional Variation in Cardiovascular Genes Enables a Tractable Genome Editing Strategy. Circulation. Genomic and Precision Medicine, e004370. -
Minimum information and guidelines for reporting a multiplexed assay of variant effect.
Claussnitzer, M., Parikh, V. N., Wagner, A. H., Arbesfeld, J. A., Bult, C. J., Firth, H. V., … Rubin, A. F. (2024). Minimum information and guidelines for reporting a multiplexed assay of variant effect. Genome Biology, 25(1), 100. -
Multisite Validation of a Functional Assay to AdjudicateSCN5ABrugada Syndrome-Associated Variants.
Ma, J. G., O'Neill, M. J., Richardson, E., Thomson, K. L., Ingles, J., Muhammad, A., … Glazer, A. M. (2024). Multisite Validation of a Functional Assay to AdjudicateSCN5ABrugada Syndrome-Associated Variants. Circulation. Genomic and Precision Medicine, e004569. -
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers.
Carrick, R. T., Gasperetti, A., Protonotarios, A., Murray, B., Laredo, M., van der Schaaf, I., … James, C. A. (2024). A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers. European Heart Journal. -
Toward Precision Medicine in the Treatment of Arrhythmogenic Cardiomyopathy
Liu, M. B., & Parikh, V. N. (2024). Toward Precision Medicine in the Treatment of Arrhythmogenic Cardiomyopathy. CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE. -
ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel: Reappraisal of Genes associated with Hypertrophic Cardiomyopathy.
Hespe, S., Waddell, A., Asatryan, B., Owens, E., Thaxton, C., Adduru, M.-L. L., … Ingles, J. (2024). ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel: Reappraisal of Genes associated with Hypertrophic Cardiomyopathy. MedRxiv : the Preprint Server for Health Sciences. -
One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy
Kim, D. S., Chu, E. L., Keamy-Minor, E. E., Paranjpe, I. D., Tang, W. L., O'Sullivan, J. W., … Ashley, E. A. (2024). One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy. FRONTIERS IN CARDIOVASCULAR MEDICINE, 11. -
Clinical features and outcomes in carriers of pathogenic desmoplakin variants.
Gasperetti, A., Carrick, R. T., Protonotarios, A., Murray, B., Laredo, M., van der Schaaf, I., … James, C. A. (2024). Clinical features and outcomes in carriers of pathogenic desmoplakin variants. European Heart Journal. -
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry.
Maurizi, N., Anthiochos, P., Owens, A., Lakdwala, N., Saberi, S., Russell, M. W., … Olivotto, I. (2024). Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry. Circulation. -
The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy.
Ahluwalia, M., Liu, J., Olivotto, I., Parikh, V., Ashley, E. A., Michels, M., … Lakdawala, N. K. (2024). The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy. JACC. Heart Failure. -
Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy.
Meisner, J. K., Renberg, A., Smith, E. D., Tsan, Y.-C., Elder, B., Bullard, A., … Helms, A. S. (2024). Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy. Circulation.
-
Early Outcomes After Extracardiac Conduit Fontan Operation Without Cardiopulmonary Bypass
Practice Locations
Center for Inherited Cardiovascular Disease at Stanford Palo Alto, CA
Palo Alto, CA
Center for Inherited Cardiovascular Disease at Stanford
300 Pasteur Dr, Heart Clinic 1 Rm A21
Palo Alto , CA 94305
Make An Appointment More Clinic Information Getting HereHeart Failure Clinic at Stanford Palo Alto, CA
Palo Alto, CA
Heart Failure Clinic at Stanford
300 Pasteur Dr, Fl 2 Rm A260
Palo Alto , CA 94305
Make An Appointment More Clinic Information Getting HereSports Cardiology Palo Alto, CA
Palo Alto, CA
Sports Cardiology
300 Pasteur Dr, Fl 2 Rm A260
Palo Alto , CA 94305
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri- Valley, or Stanford Medicine Partners. ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(40 reviews)
Dr Parikh is terrific
Staff were helpfully with directions and Rachel, Echo Tech suggested lunch at 500 Pasteur Way and it was great.
Dr Parikh is very knowledgeable and patient. She explained all the details regarding my heart condition. Highly appreciated!
Enjoyed my visit.
Absolutely exceptional!!
Exceptional! Thoughtful, compassionate and thorough
I did prior…it cant say enough great things about her.
I’m so thankful to be under her care.
Dr. Parikh is amazing. I'm so lucky to know her, and she is the reason I will continue to be seen at Stanford.
She is easy to talk to and she did check several times throughout the visit to make sure I understood everything she was saying.
Love Dr. Parikh and her team.
Doctor Parikh is a total professional, she takes the time to make sure I understand my condition and the possible treatment options. I feel like she understands my concerns and genuinely cares for my complete well being, not just my heart.
Knowledgeable and helpful. I left with a plan
Ellen, Elise and Dr. Parikh are simply the best, smartest and kindest health care people around. They make me feel like I am their most important patient. They inspire so much confidence, I literally and figuratively trust them with my life.
She was great. Answered all my questions.
I was treated like an animal and not a human being
Dr. Parikh is one of the best physicians I have ever known. She is well skilled, caring and compassionate and is helpful in shepherding her patients in making their healthcare decisions. We need more like her.
All of the staff was very attentive and helpful.
Dr. Parikh listened to my concerns and gave me several tasks to do over the next 2 weeks.
Thanks for advising me of my limitations and allowances for my prognosis.
So much of the success of these video conferences depends on the comfort level and the personality of the doctor. Dr. Parikh was definitely in the groove.
Answered all questions, and felt very comfortable
Dr Parikh is very patient, understanding, and willing to listen to my questions providing thoughtful answers. She didn’t rush me at all.
I thought she did a wonderful job.
Great medical staff
Dr. Parikh is extremely knowledgeable and treats me with care and compassion.
Absolutely. You need another category - "Excellent"
I was very pleased with my visit. Dr. Parikh was easy to talk to. She explained everything so I could easily understand my situation and what I needed to do going forward.
Definitely will recommend Dr. Parikh and his team. Very professional folks.
She is a great doctor, easy to talk to and explains things very well.
I really like Dr. Parikh. She seems to be very patient centric (as does everyone I have met at Stanford Health). She is able to explain things in a very understandable fashion.
She is wonderful.
Took the time to wait for my echo results and then showed them to me on the screen. Very informative! Thank you.
The service and attention from the physicians at my charge are excellent Dr. Parikh and Dr. Marco Perez, Victoria Parikh. Excellent thank you!
Dr. Parikh is a phenomenal physician. I felt very comfortable with her and was able to speak candidly about my concerns. I was able to easily understand, remember and follow her treatment plan.
Excellent!
detailed explanation of the causes/effects and possible solutions. this was comforting as it gave me some control back in my life
excellent care
Dr. Parikh is an attentive listener and has a sense of humor. She is fabulous in her ability to communicate & reassure.
Dr. Parikh is the best. Her office is always easy to get a hold of too. I have recommended my brother to her.
She was very knowledgeable plus friendly, which I have found hard in a speciality doctor!
Both doctors & nursing staff were exceptional & an example of how doctors should be.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone:Ìý1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
ÌÇÐÄ´«Ã½ provides comprehensive services toÌýreferÌýandÌýtrack patients, as well as the latest information and news for physicians and office staff.ÌýFor help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
Ìý
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records